【摘要】：目的觀察晚期血吸蟲病(晚血)肝纖維化治療臨床路徑的實施效果。方法選擇符合臨床路徑治療入選標(biāo)準(zhǔn)的晚血患者,制定并實施晚血抗肝纖維化治療臨床路徑方案。比較晚血患者經(jīng)實施臨床路徑治療前后的住院天數(shù)、住院總費用、個人承擔(dān)費用,以及門靜脈內(nèi)徑、肝纖維化4項指標(biāo)[透明質(zhì)酸(HA)、層黏蛋白(LN)、Ⅲ型膠原前肽(P(P)、Ⅳ型膠原(CIV)]及血清酶活性3項[丙氨酸氨基轉(zhuǎn)移酶(ALT)、天門冬氨酸氨基轉(zhuǎn)移酶(AST)和γS谷氨酰轉(zhuǎn)肽酶(γ氨酰轉(zhuǎn))]等。結(jié)果共有142例晚血患者納入抗肝纖維化臨床路徑治療�；颊咴趯嵤┡R床路徑治療后,住院總費用和患者個人承擔(dān)費用分別下降11.2%和16.1%(t=6.310、4.326,P均0.05);HA均值2倍于正常值,陽性率由70.4%升至83.1%,CC、γC.1陽性率分別為64.1%、28.9%。結(jié)論臨床路徑可大幅度降低晚血患者治療費用。但晚血患者體內(nèi)仍持續(xù)存在著纖維增生活躍和慢性肝損害現(xiàn)象,提示在臨床上仍需尋找更為有效的晚血治療方法。
[Abstract]:Objective to observe the effect of treatment of hepatic fibrosis with advanced schistosomiasis (late blood). Methods the late blood patients who met the criteria of clinical pathway therapy were selected and the clinical pathway of anti-hepatic fibrosis therapy was established and implemented. Compare the hospitalization days, total hospitalization cost, individual cost, portal vein diameter and hepatic fibrosis in patients with late blood before and after clinical path therapy [hyaluronic acid (HA), laminin (LN),] Type 鈪，

本文編號：2362343